Fusion of intracellular membrane-bound compartments is a common step in the transport of macromolecules along the endocytic and secretory pathways. A large number of factors active in the fusion process or its regulation have been identified; however, the actual sequence of events leading to membrane fusion is still unknown. In this study, we have assessed a possible role for PLA2 in endosome fusion by using an in vitro reconstitution assay and by examining endocytosis in intact cells. Several PLA2 inhibitors blocked endosome fusion in a broken-cell preparation. Inhibition was reversed by addition of arachidonic acid. At the electron microscope level, endosome clusters were observed even in the presence of inhibitors; however, actual fusion between endosomes was largely reduced. Fusion frequency increased upon the addition of arachidonic acid. A membrane-permeable PLA2 inhibitor blocked mixing of ligands internalized sequentially but did not affect internalization. The results indicate that vesicle fusion along the endocytic pathway requires a PLA2 activity. The effect of this activity would be, at least in part, mediated by arachidonic acid release.
that has been conspicuously involved in studies of exocytosis, has not been explored for other intracellular fusion events. The activity of these enzymes yields lysophospholipids and arachidonic acid (AA), two molecules that can affect membrane stability (20) . Work with model membranes suggests that certain fusogenic lipids may play a role in membrane fusion. Free fatty acids are known to enhance cation-induced fusion of chromaffin granules preaggregated by Ca2+ and synexin or calpactin (21, 22) . AA release is associated with secretion by chromaffin cells and during degranulation in neutrophils (23) . In this report, we present evidence that a PLA2 is required for in vitro endosomeendosome fusion and for the intracellular mixing of sequentially internalized ligands taken up by receptor-mediated endocytosis in intact cells. (24) . The inhibitors were solubilized in dry dimethyl sulfoxide at a concentration of 50 mM and stored at -70°C until used. Fatty acids were solubilized in ethanol at a concentration of 100 mM and stored at -70°C under a nitrogen atmosphere. Anti-NSF antibody was a generous gift of James Rothman (Sloan-Kettering Memorial Cancer Center, New York). All other reagents were from Sigma.
MATERIALS AND METHODS
In Vitro Fusion Assay. Early endosomes, prepared from J774 E-clone macrophages, were loaded with antidinitrophenol (DNP) mouse monoclonal antibody or with DNP-/-glucuronidase as described (1) . In vitro reconstitution of fusion was performed as described (1) . The fusion buffer [250 mM sucrose/0.5 mM EGTA/20 mM Hepes/KOH, pH 7.0/1 mM dithiothreitol/1.5 mM MgCl2/50 mM KCl/1 mM ATP/8 mM creatine phosphate/creatine phosphokinase (31 units/ml)/DNP-bovine serum albumin (DNP-BSA; 0.25 mg/ ml)] was supplemented with gel-filtered cytosol (1 mg/ml) (1 Routinely, endosome-enriched fractions were preincubated at 17°C for 30 min with the inhibitors and then transferred to 37°C. When required, AA solutions (5 ,ul) were dried under a stream of nitrogen in 0.5-ml microcentrifuge tubes. These tubes were used for preincubation and in vitro fusion of endosomes.
Ligand Mixing Assay. Ligand mixing assays were performed as described (25) . DNP-f-glucuronidase was incubated with J774E macrophages for 5 min at 37°C in uptake medium (1) . Internalized DNP-l3-glucuronidase was chased by incubation at 37°C. Cells were then allowed to bind aggregated anti-DNP IgG for 30 min at 4°C (26) . After two washes in ice-cold uptake buffer, cells were incubated at 17°C for 30 min in the presence of BEL. To allow ligand mixing, cells were incubated for various times at 37°C. Finally, cells were solubilized in the presence of DNP-BSA and ligand mixing was estimated by measuring /3-glucuronidase activity present in immune complexes as described (25) .
Electron Microscopy. Endosomes, loaded with mannosylated BSA-coated 5-, 10-, and 20-nm colloidal gold particles, were included in in vitro fusion reactions and vesicles were fixed in suspension as described (26) (27) (28) . Fusion (scored as vesicles containing two sizes ofgold particles) and aggregates (scored as clusters of three or more vesicles containing two or more sizes ofgold particles) were quantitated in at least 0.2 mm2.
RESULTS
Effect of PLA2 Inhibitors on Endosome Fusion. To assess whether a PLA2 activity was required for endosome fusion, several PLA2 inhibitors were tested in the in vitro endosome fusion assay, including quinacrine, dibucaine, manoalide, the mechanism-based PLA2 inhibitor, BEL, two BEL analogs ( A calcium-independent PLA2 activity was detected in both cytosol and membranes of J774 macrophages by using a modification of the PLA2 assay as described (29) . The inhibitors mentioned above blocked this PLA2 activity when added to the enzymatic assay.
Quinacrine, manoalide, and dibucaine completely inhibited fusion among endosomes (Table 1) , as did all three enol lactones ( Fig. 1 and Table 1 ). Enol lactones are compounds that liberate reactive electrophilic molecules upon hydrolysis of an internal ester bond. These compounds are not active against Ca-dependent PLA2 (24, 30) . The ED50 value for inhibition was higher than that reported for inhibition of purified PLA2. One explanation for this discrepancy is that these inhibitors compete with phospholipids, the natural substrates of the enzyme, that are abundant in the fusion assay (30) . Alternative explanations include impurities in the inhibitor, nucleophiles in the system that inactivate the inhibitor, or inaccessibility of the inhibitor to its site of action. MA, a manoalide analog, and TSA, a transition state analog, were likewise inhibitors of vesicle fusion. The most potent inhibitor was DPA, a diphosphonic acid derivate.
Most assays were carried out with BEL because its effect on PLA2 has been well characterized (24, 29, 30) . Several observations indicate that the inhibitory effect is not due to nonspecific damage of the membranes: (i) no inhibition was observed when BEL (300 AM) was added 3 min after the beginning of the fusion reaction (data not shown); (ii) when vesicles were treated with 200 ,M BEL for 30 min at 17°C, fusion was restored by washing the vesicles and adding untreated cytosol (data not shown); and (iii) no morphological damage of vesicles was observed in the presence of 200 ,uM BEL (see Fig. 3 ).
The Inhibitory Effect of PLA2 Inhibitors Is Reversed by AA. The two products ofPLA2 activity are lysophospholipids and free fatty acids (often AA). If the observed effects were due to PLA2 inhibition, the addition of exogenous lysophospholipids or free fatty acids should overcome the PLA2 block. Lysophospholipids were not able to restore fusion in the presence of BEL (lysophosphatidylcholine, -serine, -ethanolamine, and -inositol up to 50 pg/ml were tested). However, AA, the more relevant fatty acid liberated by PLA2, restored fusion in the presence of BEL ( Fig. 2A) . Fusion was inhibited by the fatty acid at concentrations >150 uM. AA also restored fusion upon treatment with MPE and DPA (data not shown). Better recovery was observed when inhibition was not complete (compare recovery in Fig. 2 A-C Only fusion blocked by PLA2 inhibitors was recovered by addition of AA. The fatty acid did not promote fusion when incubated with vesicles under conditions that do not support fusion ( Fig. 2 B and C) . Moreover, fusion recovered by AA was blocked by omitting ATP from the assay. NEM also blocked the AA-mediated fusion, suggesting a requirement for NSF. This was confirmed with anti-NSF antibody that inhibited fusion in the presence ofAA. These results indicate that AA is only one of the factors required for fusion and that other elements of the fusion mechanism, such as NSF, are necessary.
Inhibition offusion by BEL was also examined by electron microscopy. The inhibitors caused a significant decrease in the number of fusion events per square millimeter (Table 2) . However, large aggregates of endosomal vesicles, very similar to those detected in control preparations, were observed ( Fig. 3 and Table 2 ). This observation suggests that PLA2 inhibitors block fusion but not recognition between endosomes. In some instances, endosomes in close apposition, but without fusion, were observed (Fig. 3B Inset) . The number of fusion events increased significantly after AA addition ( Fig. 3C and (Fig. 4) . Inhibition was observed when the first ligand was chased for short (2.5 min) or long (30 min) periods of time. BEL did not affect internalization, as assessed by accessibility to externally added radiolabeled DNP-BSA. Moreover, the total amount of immune complex formed in the absence of scavenger was not : w e , . . . . . . . . . . . . . . . . . . . . . . . . . . 1 : : . .  ' , . i ' : i . w . ' t 4 ŵ . . . . . ' ' ' ; , N , ' . . . . . . . , ' ' affected by the inhibitor (Fig. 4) . To further rule out that BEL was somehow affecting internalization, the inhibitor was added after the internalization of mannosylated antibody. Mannosylated antibody enters through the mannose receptor and external antibody can be easily removed (25 indicate that a PLA2 activity is intimately involved in endosome fusion. PLA2 activity has been proposed to mediate secretion of amylase from pancreatic acini (32) , degranulation of rat mast cells (33) , and neurotransmitter release from chromaffin cells (34) . A role for this enzyme activity in other intracellular fusion events has only recently been evaluated. Phagocytosis is blocked by PLA2 inhibitors (35) as are macrophage adhesion and spreading (36, 37) , effects that are reversed by addition of AA. A lipid processing activity has been observed during the endoplasmic reticulum to Golgi transport (38) . A PLA2 activity has been found associated with Fc receptors (39) , and there is a preliminary report (40) of a PLA2 activity associated with NSF.
We tested several PLA2 inhibitors and found that they block endosome fusion in vitro. The inhibition was reversed by AA but not by lysophospholipids. AA is required in addition to other known fusion factors (e.g., ATP and NSF). This indicates that the fatty acid is not promoting nonspecific membrane fusion. Most of the conditions that inhibit fusion also inhibit endosome aggregation (12, 27 (25) . Inhibition by BEL, however, was almost complete.
PLA2s have several features that are potentially very interesting for the membrane fusion processes that mediate intracellular traffic. PLA2 activity generates two compounds active on membranes, lysophospholipids and AA. Lysophospholipids are able to stimulate secretion (33) and sperm acrosome reaction (41) . AA favors the transition of mem-brane bilayers to an HII phase, a lipid arrangement that may be important during membrane fusion (20) . Moreover, AA can function as an activator of other proteins and is the precursor of bioactive compounds such as prostaglandins, leukotrienes, and thromboxanes (31) . Failure of indomethacin and nordihydroguaiaretic acid to affect fusion does not completely rule out a role for AA metabolites in fusion since they may be synthesized by pathways unaffected by these inhibitors.
There are several PLA2 families (42) . The best characterized are the extracellular, 14-kDa PLA2s. Intracellular PLA2s are a growing family of proteins that exhibit a specificity for AA release. They are larger than extracellular PLA2 and require micromolar concentrations of Ca2+, probably for interaction with membranes and not for the actual hydrolysis ofphospholipids. Still some ofthem do not require Ca2+ at all. The mechanism of phospholipid hydrolysis by these PLA2 may be different from that of extracellular PLA2.
This may explain the selectivity of some PLA2 inhibitors for one or the other class of PLA2.
It is intriguing to speculate that interaction of the putative endosomal PLA2 with other components of the fusion machinery, such as GTP-binding proteins of the rab, ARF, and heterotrimeric families, protein kinases, phosphatases, NSF, and NSF-associated proteins, regulates its function in the fusion reaction. It will also be of interest to determine the role of PLA2s in other intracellular transport pathways. Tagaya and colleagues (43) have found a series of PLA2 inhibitors that block Golgi transport in vitro.
Two major regulatory mechanisms have been demonstrated in intracellular transport, protein phosphorylationdephosphorylation (15, 16) , and modulation by GTP-binding proteins (8, 11, 12) . Protein phosphorylation also modulates PLA2 activity in several systems. The effect may be direct (44) or mediated by cytoplasmic PLA2 inhibitors (e.g., lipocortins) (45) . Several plasma membrane receptors are coupled to PLA2 activity by GTP-binding proteins (46) (47) (48) (49) (50) . The putative relationship between PLA2 and signal transduction mechanisms operative in vesicle targeting remains to be elucidated.
